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Abstract
Individuals who identify as Black, indigenous, and people of color face well-
documented health disparities. A root cause is the lack of empiric evidence for or
against the use of various treatments in their medical management. This communication proposes a new benchmarking strategy for evaluating racial and ethnic representation in clinical research that can be compared across institutions with the intent of
increasing accountability for diversity and inclusion among organizations that conduct clinical research.

CO M M EN TARY
“The true neighbor will risk his position, his
prestige, and even his life for the welfare of
others.”
[Dr. Martin Luther King, Jr., On Being a Good
Neighbor 1962]
The transformational issues that surfaced in 2020 included
a resounding call for equity. Several events spotlighted long-
standing issues faced by Black, indigenous, and people of color
(BIPOC) triggering profound reflection and an immediate call
to action. The opportunity to enact meaningful change impacting health inequities may be fleeting if we fail to leverage this
opportunity. The clinical research community is in a unique position to address systemic inequities by tackling a root cause of
health disparities that exacerbates the burden faced by BIPOC
communities—inadequate representation in trials which leaves
us unable to identify the safest and most effective course of

treatment for those who are under-represented. Researchers
bear the responsibility for establishing the utility of medical
interventions in minority groups, and legislation enacted and
reauthorized over the past 30 years validates this responsibility;
explicitly mandating the reporting of racial and ethnic diversity
in federally funded clinical research with periodic evaluation
of racial and ethnic underrepresentation by the Comptroller
General.1,2 However, the nature of accountability beyond reporting remains unclear.
Recently,3 one of us examined racial and ethnic representation among children enrolled in clinical studies funded
under the Best Pharmaceuticals for Children Act (BPCA).
Diversity was explored using Simpson’s diversity index (D),
a quantitative metric representing the probability that two individuals selected at random from a population would belong
to different racial and ethnic groups (i.e., 0 = no diversity;
1 = maximal diversity; Equation 1).4 In preparing this commentary, we applied the same calculation to enrollment data
extracted from the triennial reports of the 10 largest institutes
at the National Institutes of Health (NIH),5 and observed an
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enormous degree of variability in representation across studies funded by these institutes (Figure 1). The importance of
the data published by the NIH cannot be overemphasized;
however, they lay out a number of caveats; (1) NIH “policy is
not to endorse or enforce quotas,” (2) racial and ethnic representation “depends upon a number of factors,” and (3) “enrollment figures should not be compared directly to national
census figures,” leaving limited avenue for accountability. In
this commentary, we are proposing that accountability begin
at the local level in the communities we serve with the patients we treat and we have constructed a simple, singular,
scalable metric, the “representation quotient” (RQ).
As a measure of representation, the diversity index consolidates individual subgroup statistics into a singular value.
By way of example, our BPCA review considered 14 racial
and ethnic subgroups derived from the combination of seven
racial groups (American Indian or Alaskan Native, Asian
American, Black, Hawaiian or Pacific Islander, multiracial, not reported or unknown, and White) with two ethnic
groups (Hispanic and non-Hispanic). However, the number
of subgroups available for diversity index calculation will
vary depending on the level of detail reported and the index
itself lacks a standard for comparison. The proposed RQ is
obtained by calculating the diversity index of the research
participant population (Drp) and dividing the value by the diversity index of the reference population (DRP) determined
by sampling the general population at the same geographic
frequency as the research participant population. Estimates
of variance (σ²) are calculated to define bounds for the value
(Equation 2).4,6

F I G U R E 1 Enrollment diversity for the top 10 NIH institutes
over the most recent 3 reporting years. NCI, National Cancer Institute;
NHLBI, National Heart, Lung, and Blood Institute; NIA, National
Institute on Aging; NIAID, National Institute of Allergy and Infectious
Diseases; NICHD, Eunice Kennedy Shriver National Institute of
Child Health and Human Development ; NIDA, National Institute on
Drug Abuse; NIDDK, National Institute of Diabetes and Digestive
and Kidney Diseases; NIGMS, National Institute of General Medical
Sciences; NIH, National Institutes of Health; NIMH, National Institute
of Mental Health; NINDS, National Institute of Neurological Disorders
and Stroke
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An RQ greater than 1 signals diversity in the clinical research population that exceeds that of the reference population while an RQ less than 1 suggests that the clinical research
population is less diverse than the reference population. In
the case of an individual organization, such as Children’s
Mercy, both the numerator and denominator reflect the population being served by that specific institution. Accordingly,
the RQ is agnostic to the overarching population composition
allowing insight into representation efforts for clinical studies irrespective of population diversity in the communities
where organizations are located. This enables an apples-to-
apples comparison between organizations and circumvents
the challenge of quotas.
Trialing the RQ at our organization, we collected metrics on clinical research participation and recorded corresponding challenges in data acquisition to illuminate
deficiencies and propose system improvements for enhancing the quality of these measures. Data from enrollment in
federally funded studies were extracted from all research
performance progress reports (RPPR) submitted to the NIH
through the Research & Grants Administration office over
the most recent 5-year period. The geographic distribution
of patients we serve was pulled from patient encounter data
maintained by the organization and the DRP determined by
extracting county level data from the US Census Bureau.7
Importantly, senior leaders were approached before undertaking this analysis to ensure support at the highest level of
leadership regardless of what the data would subsequently
reveal.
Our findings indicated that diversity among our clinical
research participants exceeded that of the population we
serve in 3 of the last 5 years, but fell significantly short in
the other 2 years, giving Children’s Mercy a 5-year rolling
average RQ of 0·89 (Figure 2). Because the RQ is calculated
using all of the data one typically uses to examine representation, we can perform a more detailed interrogation of the RQ
inputs to identify the extent to which population subgroups
are over-or under-represented in our trials. In doing so, we
observed consistent under-representation of Hispanic, and to
a lesser extent Asian American, children in our studies (data
not shown). We also discovered that several individual studies recorded high rates of unknown race and ethnicity, despite
the reporting requirements mandated by the NIH, contributing to year-over-year fluctuations.
There are limitations to the conclusions we can draw from
the RQ. For example, we cannot discriminate whether under-
represented populations are approached at different frequencies or elect to participate at different rates. We also do not
know the extent to which the observations are influenced by
the inclusion of studies for conditions which have inherent
imbalances with respect to disease epidemiology, healthcare utilization patterns, medication utilization, access to
care, or prescriber treatment bias. Nevertheless, it represents
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F I G U R E 2 Children’s Mercy Hospital
annual RQ for the preceding 5 years. Drp-
diversity index of the research participant
population, DRP-diversity index of the
reference population

a current snapshot of clinical research participation at our
organization.
In the process of conducting this analysis, we uncovered several information gaps that we believe are important
enough to initiate system-wide changes in our organization.
An unbiased snapshot of research participation requires an
objective data source that is independent of a willingness to
disclose. Although the RPPR reflect the desired data, they
do not represent the entirety of clinical research activities at
our institution. The availability of a clinical trial management system (CTMS), which we are currently deploying, can
supplement RPPR reports but it will not entirely resolve the
data challenge as CTMS will only contribute data from studies incurring patient care costs. Thus, participation in other
types of research (e.g., community-based studies, psychosocial research, quality-of-life studies, epidemiologic research,
genetic studies, etc.) remains unaccounted for in our current
system resulting in an incomplete picture of racial and ethnic
outreach in our clinical research program. The changes we
are considering to address these challenges include mandated
institutional reporting across all studies, a thorough examination of the barriers that investigators encounter in obtaining this information, creation of a dashboard that provides
real-time metrics for our organization, and refinement of educational strategies to emphasize the importance of representation in clinical research.
The incomplete nature of our data led to debate among
the authors regarding the merit in reporting our findings and
the prematurity of a purposeful call-to-action for others to
follow suit; however, we concluded that the utility in doing
so is multifaceted:
1. First and foremost is elevated awareness. By adopting
the RQ as a starting point and including it as part of
our common metrics, we reinforce the principle that
diversity and inclusion are expected to be part of every
conversation related to research—in essence establishing
a new normal.
2. Publicly releasing our data serves to promote transparency, underscore our commitment to accountability
within the communities who partner with us in doing this

research, and drive institutional changes to address the inadequacies we uncover.
3. These data offer a quantitative baseline on which to measure improvement efforts. The RQ provides an objective
metric that accounts for regional population differences
thereby laying the foundation for benchmarking initiatives that define racial and ethnic research representation against a national average in the same way that has
been adopted for interventional procedures and disease
outcomes.8,9
We realize that resource limitations invariably restrict
the scope and magnitude of clinical research projects.
Moreover, simply committing to balanced racial and ethnic representation does not ensure that studies are powered
to answer important questions related to effectiveness and
impactfulness in every population subgroup. However, tolerating racial and ethnic imbalance in studies (apart from
those of diseases affecting racial subgroups) requires an
open and honest acknowledgment that the generalizability
of the resultant research findings is severely restricted, and
we hope that these frequent admissions will lead the clinical research community to reassess the current research
enterprise.
We conclude with a challenge to our colleagues. If racial and ethnic representation in research is a publicly stated
goal of your organization, please join us by submitting your
unbiased, de-identified research participation data for representation on a national benchmarking website we are hereby
committing to create and support. The platform will display
RQ on the homepage as the primary metric allowing organizations to benchmark against others of similar size and
scope. Subpages will offer a deeper dive into subpopulation
specific details so that prospective research partners (e.g.,
public and private funding agencies and research collaborators) can identify sites that (1) alone, or in combination,
offer the greatest likelihood of meeting clinical trial needs
and (2) provide objective evidence of having made a public
commitment to ensuring racial and ethnic representation.
Until we stand-up the public facing website with details on
data submission, please contact the corresponding author
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for the requirements for the inclusion of your organizations
data.
We are committed to making transparent the successes
and failures in our journey, no matter how uncomfortable it
makes us, or how damaging to our prestige, and we believe
that if enough organizations make the same commitment by
standing together, we can achieve meaningful change on behalf of the patients we serve.
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where, s is the individual racial and ethnic subgroup, n is the
total number of children in each subgroup, N is the total number
of children across all subgroups.
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